[go: up one dir, main page]

KR920019371A - 안정화된 인자 ⅷ 제제 - Google Patents

안정화된 인자 ⅷ 제제 Download PDF

Info

Publication number
KR920019371A
KR920019371A KR1019920005733A KR920005733A KR920019371A KR 920019371 A KR920019371 A KR 920019371A KR 1019920005733 A KR1019920005733 A KR 1019920005733A KR 920005733 A KR920005733 A KR 920005733A KR 920019371 A KR920019371 A KR 920019371A
Authority
KR
South Korea
Prior art keywords
solution
activity
amino acid
factor vii
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019920005733A
Other languages
English (en)
Other versions
KR100231398B1 (ko
Inventor
프뢰덴베르크 빌프리드
Original Assignee
스타인, 부크
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6429102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920019371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 스타인, 부크, 베링베르케 아크티엔게젤샤프트 filed Critical 스타인, 부크
Publication of KR920019371A publication Critical patent/KR920019371A/ko
Application granted granted Critical
Publication of KR100231398B1 publication Critical patent/KR100231398B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

안정화된 인자 Ⅷ 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 아미노산 또는 이의 염 또는 유도체중의 하나 및 필요에 따라, 청정제 및 유기 중합체를 함유하는 인자 Ⅷ : C 활성을 갖는 용액.
  2. 제1항에 있어서, 아미노산이 천연 아미노산인 용액.
  3. 제1항에 있어서, 아미노산이 염기성 아미노산인 용액.
  4. 제1항에 있어서, 아르기닌과 글라이신을 함유하는 용액.
  5. 제1항에 있어서, 아미노산의 농도가 0.001 내지 1㏖/ℓ인 용액.
  6. 제1항에 있어서, 유기 중합체 또는 비이온성 청정제를 함유하는 용액.
  7. 제1항에 있어서, F Ⅷ : C 활성이 혈장중에서 나타나는 형태의 사람인자 Ⅷ 또는 유전공학적으로 조작된 인자 Ⅷ : C 또는 이들의 유도체로부터 유도되는 용액.
  8. 제1항에 있어서, 특이 F Ⅷ : C 활성이 적어도 1000IU/㎎인 용액.
  9. 제1항에 따른 용액을 함유하는 약제.
  10. 제9항에 있어서, 통상적으로 약학적으로 적합한 안정화 및/또는 완충물질을 함유하는 약제.
  11. 제10항에 있어서, 탄수화물을 함유하는 약제.
  12. 아미노산 또는 이의 염 또는 유도체중의 하나 및, 필요할 경우, 유기 중합체 또는 청정제를 인자 Ⅷ : C 활성을 갖는 용액에 가함을 특징으로 하여 제1항에 따른 용액을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920005733A 1991-04-09 1992-04-07 응고인자 viii 활성을 지닌 안정화된 액제 Expired - Lifetime KR100231398B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4111393.4 1991-04-09
DE4111393A DE4111393A1 (de) 1991-04-09 1991-04-09 Stabilisierte faktor viii-praeparationen

Publications (2)

Publication Number Publication Date
KR920019371A true KR920019371A (ko) 1992-11-19
KR100231398B1 KR100231398B1 (ko) 1999-11-15

Family

ID=6429102

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920005733A Expired - Lifetime KR100231398B1 (ko) 1991-04-09 1992-04-07 응고인자 viii 활성을 지닌 안정화된 액제

Country Status (12)

Country Link
US (1) US5565427C1 (ko)
EP (1) EP0508194B1 (ko)
JP (2) JP3777467B2 (ko)
KR (1) KR100231398B1 (ko)
AT (1) ATE160942T1 (ko)
AU (1) AU651188B2 (ko)
CA (1) CA2065553C (ko)
DE (2) DE4111393A1 (ko)
DK (1) DK0508194T3 (ko)
ES (1) ES2111579T4 (ko)
GR (1) GR3025873T3 (ko)
IE (1) IE921124A1 (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0627924T3 (da) * 1992-10-02 2001-04-30 Genetics Inst Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator
SE9302006D0 (sv) * 1992-10-02 1993-06-11 Kabi Pharmacia Ab Protein formulation
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6586573B1 (en) 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
CN1245216C (zh) 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
CN1756559B (zh) 2003-01-08 2010-04-28 诺华疫苗和诊断公司 稳定的含组织因子通路抑制剂或组织因子通路抑制剂变体的液体组合物
HUE058897T2 (hu) * 2003-02-26 2022-09-28 Nektar Therapeutics Polimer VIII-as faktor egység konjugátumok
DE10333317A1 (de) † 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
CA2591852A1 (en) 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
EP1899462B1 (en) * 2005-07-02 2011-03-09 Arecor Limited Stable aqueous systems comprising proteins
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
DK2126106T3 (en) * 2007-02-23 2017-12-04 Sk Chemicals Co Ltd Process for the preparation and purification of Factor VIII and its derivatives
BRPI0810500A2 (pt) 2007-04-26 2014-10-14 Bayer Healthcare Llc Estabilização de soluções líquidas de proteína recombinante para armazenagem no estado de congelamento
CA2732423A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
AU2009289212B2 (en) * 2008-09-03 2015-02-12 Octapharma Ag New protecting compositions for recombinantly produced factor VIII
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
KR20180126103A (ko) 2009-06-09 2018-11-26 프로롱 파마슈티컬스, 엘엘씨 헤모글로빈 조성물
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
EA032336B1 (ru) * 2010-09-17 2019-05-31 Баксалта Инкорпорейтид Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
KR101948337B1 (ko) 2010-11-05 2019-02-14 박스알타 인코퍼레이티드 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체
CN103703141B (zh) 2011-04-08 2016-08-17 伯乐实验室公司 具有降低的非特异性活性的pcr反应混合物
JP6060447B2 (ja) 2011-04-08 2017-01-18 バイオ−ラッド ラボラトリーズ インコーポレーティッド 非特異的活性が低下したＳｓｏ７ポリメラーゼコンジュゲート
US9394353B2 (en) 2011-10-18 2016-07-19 Csl Limited Method for improving the stability of purified factor VIII after reconstitution
CN102580062B (zh) * 2012-03-09 2017-03-08 中国医学科学院输血研究所 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂
JP2014138614A (ja) * 2014-04-09 2014-07-31 Sk Chemicals Co Ltd 第ｖｉｉｉ因子とその誘導体の製造及び精製方法
EP3177317B1 (en) 2014-08-04 2020-03-18 CSL Limited Factor viii formulation
EP3994162A1 (en) 2019-07-04 2022-05-11 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB941019A (en) * 1961-04-27 1963-11-06 Crookes Lab Ltd Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4650858A (en) * 1983-03-21 1987-03-17 Nordisk Gentofte A/S Concentrate of the antihemophilic factor VIII and a process for producing it
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
JP4021982B2 (ja) * 1998-03-03 2007-12-12 信越化学工業株式会社 ハイブリッド型ウイグラ

Also Published As

Publication number Publication date
US5565427C1 (en) 2002-07-23
AU651188B2 (en) 1994-07-14
ES2111579T4 (es) 2011-12-29
ATE160942T1 (de) 1997-12-15
DE4111393A1 (de) 1992-10-15
KR100231398B1 (ko) 1999-11-15
DE59209051D1 (de) 1998-01-22
CA2065553C (en) 2003-06-10
JPH0597702A (ja) 1993-04-20
JP3809501B2 (ja) 2006-08-16
JP2002097199A (ja) 2002-04-02
DK0508194T3 (da) 1998-08-24
AU1470292A (en) 1992-10-15
US5565427A (en) 1996-10-15
JP3777467B2 (ja) 2006-05-24
EP0508194B1 (de) 1997-12-10
IE921124A1 (en) 1992-10-21
ES2111579T3 (es) 1998-03-16
CA2065553A1 (en) 1992-10-10
EP0508194A1 (de) 1992-10-14
GR3025873T3 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
KR920019371A (ko) 안정화된 인자 ⅷ 제제
ES2526707T3 (es) Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos
DE69434418D1 (de) Orale Dareichungsform
NO993709D0 (no) Stabilisert blanding omfattende fibrinogen
KR950703987A (ko) G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf)
DE69230610D1 (de) Peptide mit zyklischen Hauptketten, deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE69522562D1 (de) Eine glucagon enthaltende pharmazeutische zubereitung
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
KR950700728A (ko) 약제형 및 그밖의 다른 복용형(Pharmaceutical and other dosage forms)
KR940008681A (ko) 디클로페낙 염용 비경구 용액
KR960034408A (ko) 안정한 트란스글루타미나제 제형 및 이의 제조방법
KR910009246A (ko) 폴리펩타이드를 함유하는 피하투여용 또는 근육내 투여용 약제
ATE124869T1 (de) Stabilisierung von calcitonin enthaltenden pharmazeutischen verbindungen.
KR970706841A (ko) 성장호르몬 및 루신으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and leucine)
DE69837997D1 (de) Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels
BR9809103A (pt) Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos
KR950024769A (ko) 고농도 tcf 제제
KR950005325A (ko) 제약 조성물
KR910005886A (ko) 안정화 백혈구 인터페론
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
DE60001489D1 (de) Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
ATE149354T1 (de) Pharmazeutische zusammensetzung von stabilisiertem (leu 13>-motilin-hse
DE69423623D1 (de) Aminosäureergänzung

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920407

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970131

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920407

Comment text: Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19980217

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19990129

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19990623

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19990830

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19990831

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20020626

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20030825

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20040823

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20050824

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20060824

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20070808

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20080825

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20090824

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20100825

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20110719

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20110719

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20130109

Termination category: Expiration of duration